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ABSTRACT: The known genetic cause of Hun-
tington’s disease (HD) has fueled considerable progress in
understanding its pathobiology and the development of
therapeutic approaches aimed at correcting specific
changes linked to the causative mutation. Among the
most promising is reducing expression of mutant hunting-
tin protein (mHTT) with RNA interference or antisense oli-
gonucleotides; human trials are now being planned. Zinc-
finger transcriptional repression is another innovative
method to reduce mHTT expression. Modulation of mHTT
phosphorylation, chaperone upregulation, and autophagy
enhancement represent attempts to alter cellular homeo-
stasis to favor removal of mHTT. Inhibition of histone
deacetylases (HDACs) remains of interest; recent work
affirms HDAC4 as a target but questions the assumed
centrality of its catalytic activity in HD. Phosphodiesterase
inhibition, aimed at restoring synaptic function, has pro-
gressed rapidly to human trials. Deranged cellular signal-
ing provides several tractable targets, but specificity and
complexity are challenges. Restoring neurotrophic sup-
port in HD remains a key potential therapeutic approach.
with several approaches being pursued, including brain-
derived neurotrophic factor (BDNF) mimesis through tyro-
sine receptor kinase B (TrkB) agonism and monoclonal
antibodies. An increasing understanding of the role of glial
cells in HD has led to several new therapeutic avenues,
including kynurenine monooxygenase inhibition, immuno-
modulation by laquinimod, CB2 agonism, and others. The
complex metabolic derangements in HD remain under
study, but no clear therapeutic strategy has yet emerged.
We conclude that many exciting therapeutics are pro-
gressing through the development pipeline, and combin-
ing a better understanding of HD biology in human
patients, with concerted medicinal chemistry efforts, will
be crucial for bringing about an era of effective therapies.
VC 2014 The Authors. Movement Disorders published by
Wiley Periodicals, Inc. on behalf of International Parkinson
and Movement Disorder Society.
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Huntington’s disease (HD) is characterized by a
number of certainties: It is inherited, fully penetrant,
neurodegenerative, progressive, fatal, and caused by
CAG repeat expansions in the gene encoding hunting-
tin. So far, another certainty has been the failure of
every attempt to prevent or slow its progression in
patients and mutation carriers.1 However, the known
cause of HD and our ever-increasing understanding of
the events that connect the mutation to the clinical
features of the disease continue to inspire confidence
that one or more dysfunctions leading to HD will
prove tractable. Here we review those therapeutic tar-
gets in the pipeline, borne from our understanding of
the diverse effects of the HD mutation, that we con-
sider most likely to give rise to viable treatments that
may reach clinical trials in the foreseeable future. Fig-
ure 1 gives an overview of the targets we discuss, and
these are summarized in Table 1.
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Reducing Huntingtin Expression
In contrast to other prevalent neurodegenerative disor-
ders, the known genetic cause of HD allows the known
pathogenic entity, mutant huntingtin protein (mHTT),
to be targeted with certainty. Lowering expression of
mHTT at the level of DNA (transcription) or RNA
(translation) ought to reduce all of the downstream dele-
terious effects of the protein that lead to the manifesta-
tions of HD. Such strategies are sometimes known as
“gene silencing”—somewhat misleadingly, because no
approach is expected to stop mHTT expression alto-
gether—or “huntingtin lowering” or “huntingtin
suppression”. These approaches aimed at reducing HTT
expression are considered among the most promising
emerging therapeutics to slow or prevent HD.2,3
Three broad approaches are under investigation to
reduce mHTT expression: RNA interference (RNAi)
using short interfering RNA (siRNA); translational
repression using single-stranded DNA-based antisense
oligonucleotides (ASOs); and transcriptional repression
using zinc finger proteins (ZFPs).
Some of these approaches constitute “gene
therapy”—namely, those delivered or expressed using
viral technology, such as ZFPs or some RNAi meth-
ods, whereas central nervous system (CNS) delivery of
antisense oligonucleotides or siRNAs is not gene
therapy.
Nucleotide-Based Silencing
RNA interference and ASO repression use synthetic
modified nucleotide agents designed to bind to a cho-
sen sequence in the HTT messenger RNA (mRNA),
using Watson-Crick complementarity. Once bound,
different cellular mRNA disposal mechanisms remove
the HTT mRNA, resulting in reduced translation and
lowered protein expression (Fig. 2).2,4
In RNAi, the drug molecule can be either an siRNA
or a microRNA (miRNA) molecule. Degradation of
siRNA-bound mRNA is performed by the RNA-
induced silencing complex (RISC), which incorporates
the RNAse enzyme argonaute. The ASOs are modified
FIG. 1. Schematic depicting current priority preclinical therapeutic targets under investigation for Huntington’s disease. HTT, huntingtin; KMO, kynu-
renine monooxygenase; NMDA, N-methyl-D-aspartate; PDE, phosphodiesterase; BDNF, brain-derived neurotrophic factor; HDAC, histone deacety-
lase; Trk, tropomyosin-related kinase. Adapted from Ross et al.36
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single-stranded DNA molecules, and ASO-bound
mRNA is degraded by RNAse H (Fig. 2).5
Nucleotide-based gene silencing methods have
advanced considerably in recent years and are
approaching readiness for trials in human HD
patients. Numerous successes have now been reported
in rodent models, first with RNA-based drugs6 and
more recently with ASOs.7 Most animal work has
focused on nonselective silencing of both wild-type
and mutant HTT alleles, and the first human trials
will take this approach. Directly infused into the brain
parenchyma or ventricles of HD model mice, these
drugs appear capable of significantly reducing mRNA
expression and HTT protein levels. This has been
associated with not just slowing of the phenotypic
progression of HD, but with substantial improvement
in some manifestations having clinically significant
counterparts in the human disease. For instance, intra-
striatal injection of an adeno-associated virus (AAV2)
vector expressing HTT-silencing miRNA in the
YAC128 HD mouse model produced transduction of
approximately 80% of the striatum, approximately
50% reduction in HTT mRNA, and a similar reduc-
tion in HTT protein; reduced mHTT aggregation;
restored performance on a behavioral task modeling
depression to near-wild-type levels; and showed no
evidence of inflammation or neurotoxicity.8 The ASOs
are no less successful: intraventricular infusion in three
HD mouse models produced more than 60% reduc-
tion in HTT mRNA and more than 80% reduction in
HTT protein; mHTT aggregate formation was delayed
and motor performance improved with treatment.
Strikingly, these improvements significantly outlasted
both the presence of the ASO drug and the reduction
in soluble protein,9 suggesting that dysfunctioning
cells are able to recover from at least some deleterious
effects of mHTT if expression of the protein is even
transiently reduced, restoring the balance of damage
and repair. Of course, whether this optimistic
“huntingtin holiday” concept will translate into
human patients for these therapeutics remains to be
seen.10,11
In 2013, the first phase 1 human trial of an intrathe-
cally delivered ASO, targeting superoxide dismutase 1
(SOD1) in familial amyotrophic lateral sclerosis, was
completed without significant safety issues reported, pav-
ing the way for such trials with such agents in HD.12
Potential Risks of Gene Silencing
Lowering huntingtin expression is not without its
challenges. Safety is a major concern: both off-target
effects and on-target lowering of wild-type HTT levels
could produce unforeseen consequences in humans.
The corollary of sustained benefit may be sustained
adverse effects and the absence of an “off-switch,” par-
ticularly for gene therapy approaches such as ZFP, and
viral delivery of siRNAs or miRNAs, but also for long-
lasting drugs such as ASOs, is cause for proceeding
with caution to human trials. A major unknown is the
effect of lowering wild-type HTT in humans. HTT is
clearly an important protein, because knocking out the
gene is embryonic lethal in murine models,13 and con-
ditional huntingtin knockout has been reported to pro-
duce neurodegeneration.14 Although transient long-
acting ASO-induced HTT knockdown in wild-type
BACHD mice by 75% produced no detectable behav-
ioral or motor deficits,9 subtler effects could be missed
in murine studies, and the effect of reducing wild-type
HTT in human patients is unknown. However, we do
know with certainty that mHTT expression causes
HD; therefore, we hope that the benefits of lowering
the toxic mHTT protein will significantly outweigh the
potential side effects of lowering wild-type HTT.
Other safety concerns are generic to the molecules
and delivery methodologies necessary to obtain transla-
tional repression in the CNS. The presence of synthetic
oligonucleotides per se, some with backbone chemis-
tries not seen in nature, could cause toxicity or neuro-
inflammation independently of their effects on gene
expression.15 Although the safety and efficacy of viral
vectors is improving, concerns remain around their
possible immunogenicity, either on first dosing16 or as
a limitation to the later administration of newer AAV-
delivered compounds to patients dosed previously.
Future oligonucleotide-based gene silencing drugs
are likely to be even more effective. Candidate nucleo-
tide sequences have been optimized through rational
design to maximize binding to HTT mRNA while
minimizing off-target effects through binding to other
mRNAs,17 whereas improvements in the nucleotide
backbone chemistry promise improved specificity,
potency, and stability.18
So far, the available safety data, especially from sev-
eral recent nonhuman primate trials, are encouraging. In
wild-type rhesus macaques, McBride and colleagues19
produced up to 45% sustained wild-type HTT reduction
in the striatum using AAV-delivered shRNA without evi-
dence of adverse effects; Grondin and colleagues20 dem-
onstrated safety of AAV-mediated RNAi striatal wild-
type HTT suppression over six months; Stiles and col-
leagues21 found 28 days’ convection-enhanced siRNA
delivery to be well tolerated; and ASOs infused into the
lumbar cerebrospinal fluid produced distribution to the
cortex and, to a lesser extent, some deep brain struc-
tures, without adverse effects.22
Allele-Selective Silencing
One way to obviate the risk of WT HTT knock-
down is to target the mutant allele selectively. Target-
ing the CAG repeat to achieve allele-selective
knockdown is under investigation23 but carries a risk
of off-target effects on other polyCAG-containing
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genes. Another strategy is to identify and target single-
nucleotide polymorphisms (SNPs) on the mutant
allele, an approach that may be able to provide allele-
selective mHTT silencing for a certain percentage of
HD mutation carriers, amounting to personalized
genomic medicine in which individual subjects with
the correct SNP genotype on the mutant allele may be
treated.7,24 The existence of a few common haplotypes
means some SNPs are overrepresented on alleles also
bearing HTT expansions, suggesting that a small num-
ber of SNP-targeted drugs could provide allele-
selective silencing for most individuals.24 However,
targeting polymorphisms dramatically reduces the rep-
ertoire of possible RNA target sequences, increasing
the chance of off-target effects; developing multiple
agents, each targeting a different SNP, has significant
regulatory, cost, and practical implications. Non-
allele–selective approaches are much more likely to
reach human trials sooner, because such agents are
more advanced in the HD therapeutic pipeline; but
both approaches are being actively developed.
The Distribution Problem
The other major challenge is delivery and distribu-
tion of the HTT suppression agents in the CNS.
Whereas in nonhuman primates, ASOs diffuse rather
widely into the cortex when injected into the lumbar
cerebrospinal fluid, their distribution is not universal,
and in particular the striatum, affected prominently
and early in HD, absorbs relatively little after lumbar
injection.22 The siRNAs have even less natural diffu-
sion and uptake, but this can be enhanced by a num-
ber of methods, including viral vectors, exosomes,25
cholesterol conjugation,26 convection-enhanced deliv-
ery, and novel conjugates of single-stranded siRNA
compounds.27,28 Targeting both cortex and striatum
using different delivery methods has been proposed to
overcome these limitations, and we think this may be
an important future therapeutic approach.11 This is
supported by recent work demonstrating that reducing
mHTT expression in both cortex and striatum is nec-
essary for optimal suppression of relevant phenotypes
in a murine model of HD.29 Meanwhile, the develop-
ment of technologies such as the Roche “brain
shuttle” raises the prospect of allowing CNS penetra-
tion by peripheral administration of potential thera-
peutic agents.30
Zinc Fingers
Another exciting advance uses zinc finger protein
repressors, which are transcription factor DNA-
recognition motifs that can be designed to allow selec-
tive binding to specific DNA sequences, and fused to a
transcriptional repressor domain (Fig. 2). Zinc-finger
proteins (ZFPs) can repress protein production by
reducing transcription.31 In theory, this combines the
virtues of RNAi translational repression with the
added advantages of obviating potential harm from
toxicity of mHTT mRNA32 or from alternatively
spliced HTT species that may lack the targeted mRNA
sequence33—pathobiological mechanisms that have
both been proposed in HD. Two groups have targeted
the expanded CAG repeat that causes HD using ZFP-
based compounds encoded by viral vectors. Serendipi-
tously, the proximity of the CAG repeat to the 5’ end
of the HTT gene appears to confer considerable selec-
tivity over other polyCAG-containing genes. The
approach has so far demonstrated successful selective
repression of mHTT and amelioration of motor mani-
festations in an HD mouse model, but it shares the
delivery and distribution hurdles of other virally deliv-
ered HTT-lowering methods.3,34 The ability of ZFPs to
target nuclease-induced DNA scission and repair raises
the tantalizing prospect of true gene therapy for HD in
which excessive CAGs are excised from the genomes
of expansion carriers through “genome editing.”35
Protein Homeostasis
Once expressed, mHTT interacts with hundreds of
partners, undergoes dozens of post-translational modi-
fications, forms intranuclear and cytoplasmic aggre-
gates, and may be degraded through autophagy. The
complex life of mHTT in cells offers a multitude of
potential therapeutic targets.1,36 Prioritizing these is
currently limited by a lack of understanding of the
most toxic HTT species and the difficulty of modulat-
ing multifunctional targets.
Modulation of mHTT post-translational modifica-
tion is appealing because it is carried out by enzymes
that ought to be targetable by small molecule thera-
peutics (Fig. 1). Phosphorylation of N-terminal mHTT
FIG. 2. Schematic illustration of the three main approaches to lowering
huntingtin expression. Zinc finger protein (ZFP) therapeutics aim to
reduce transcription of the huntingtin gene. Translational repression
can be attempted at the pre-mRNA level using DNA-based antisense
oligonucleotides (ASOs) or on mature mRNA using short interfering
RNA (siRNA) compounds. Different cellular mechanisms degrade the
bound mRNA.4
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at serines 13 and 16 reduces its toxicity in vivo37 and
affects its intracellular targeting,38 whereas phospho-
rylation at serine 421 restores the ability of mHTT to
promote axonal vesicular transport and neurotrophic
factor release.39 Small-molecule kinase inhibitors mod-
ulating N-terminal mHTT phosphorylation have been
identified and are under investigation,38 but whether
inhibitors that can specifically increase desirable phos-
phorylation of key residues, while avoiding harmful
phosphorylation events elsewhere in mHTT, or other
proteins, remains to be seen. The same is true of all
potentially important post-translational modification.
One striking recent report linked to post-translational
modification concerns gangliosides—CNS-abundant
glycosphingolipids with roles in membrane functioning
and cell signaling that have been shown to be deficient
in HD models.40 Chronic intraventricular infusion of
ganglioside GM1 in YAC128 mice restored normal
motor function and expression of the striatal marker
DARPP32 and increased phosphorylation of HTT at
serines 13 and 16.41 The mechanism of this intriguing
result is unclear: It requires replication and further
mechanistic study as a possible therapeutic avenue.
Although whether mHTT aggregates are neuropro-
tective, neurotoxic, or both remains unclear, disor-
dered protein folding and aggregation are a potentially
tractable hallmark of HD. Upregulation of chaperone
proteins in an attempt to reduce harmful misfolding of
mHTT has previously shown limited therapeutic
potential in mammalian HD models.42,43 However,
overexpression of HSJ1a in R6/2 mice was shown to
reduce the formation of large nuclear aggregates and
modestly delayed disease progression, surprisingly
mediated by detergent-insoluble mHTT species that
had already begun to aggregate.44 Another chaperone,
TCP1-ring complex (TRiC), is known to suppress
mHTT aggregation,45,46 and a recombinant subunit of
TRiC, ApiCCT1, was recently shown to be able to
enter cells, where it decreased the formation of visible
inclusions and fibrillar oligomers and reduced mHTT-
induced toxicity.47 Whether this is a viable therapeutic
strategy remains to be seen, but an increased under-
standing of chaperone proteins and protein homeosta-
sis is capable of generating novel, apparently tractable
therapeutic targets.
Mutant huntingtin protein can be cleared by macro-
autophagy but impairs its own clearance through
impaired cargo recognition.48 Enhancing autophagy
through mammalian target of rapamycin (mTOR) inhi-
bition by rapamycin improved phenotypes in fly and
mouse models of HD,49 and a number of agents have
shown similar effects in model systems,50 and upregu-
lation of autophagy to clear mHTT is an important
potential therapeutic strategy. A cellular imaging
screen for autophagy enhancers revealed a candidate
compound that was neuroprotective against mHTT
and several related FDA-approved compounds with
similar potential.51 Acetylation of mHTT targets it for
degradation by autophagy49 and more generally, hypo-
acetylation of chromatin is a feature of HD, so pro-
moting acetylation has been proposed as a therapeutic
strategy. Selisistat, an inhibitor of the deacetylase sir-
tuin 1, was recently shown to suppress mHTT-induced
pathology in Drosophila, mammalian HD cell models,
and the R6/2 mouse, where it significantly improved
survival and behavioral but not motor phenotype, and
reduced aggregate formation.52 Whether this was
accomplished through autophagy enhancement or
another means is unclear, and the role of sirtuin 1 is
controversial, its overexpression in HD mammalian
models also having been reported as neuroprotective.53
A recent phase 1B clinical trial of selisistat in early HD
demonstrated safety and tolerability.54
Histone Deacetylase Inhibition
With the aim of correcting transcriptional dysregula-
tion, histone deacetylase (HDAC) inhibitors have been
under study for a number of years in HD. The
HDACs are potent regulators of transcription through
chromatin modification. The nonselective HDAC
inhibitor suberoylanilide hydroxamic acid was shown
to ameliorate the motor phenotype in R6/2 mice.55
Although compounds targeting HDAC1 and HDAC3
have been shown to ameliorate disease phenotypes in
fly and cellular models,56 systematic work has shown
HDAC4 to be the sole HDAC among 11 whose
genetic knockdown ameliorates the HD phenotype in
mouse models.57-60 HDAC4 inhibition has therefore
been a focus for therapeutic development in HD, and
potent, selective small-molecule inhibitors of its enzy-
matic function have been developed.61
Unexpectedly, though genetic HDAC4 knockdown
improved neuropathology, synaptic function, motor
phenotype, and lifespan in R6/2 mice, it did so with-
out improving global transcriptional dysregulation.
These double-transgenic animals show delayed cyto-
plasmic mHTT aggregation, and HDAC4 is now
known to co-localize with cytoplasmic inclusions.57
This novel, cytoplasmic role for HDAC4 calls into
question whether inhibition of its catalytic site is nec-
essary or sufficient to recapitulate the strikingly favor-
able features of genetic HDAC4 knockdown. A
reappraisal of the therapeutic effect of suberoylanilide
hydroxamic acid in HD model mice revealed that it
reduced HDAC4 level through increased degrada-
tion.62 Understanding and modulating the noncatalytic
functions of HDAC4 is a focus of current study.
Phosphodiesterase Inhibition
Altered synaptic plasticity is one potentially reversi-
ble cause of dysfunction in HD. Impairment of cyclic
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adenosine monophosphate (cAMP) signaling63 and
dysregulation of gene transcription mediated by the
cAMP response element (CRE)64 are established fea-
tures of HD. Phosphodiesterase (PDE) 10A is almost
exclusively expressed in the striatum,65 and its activity
is intimately linked to the synaptic biology of medium
spiny neurons whose death is a prominent feature of
HD. PDE10A regulates cAMP and cyclic guanosine
monophosphate signalling, synaptic plasticity and the
response to cortical stimulation.66,67 PDE10A inhibi-
tion or genetic deletion produces numerous CRE–
related gene expression changes68 and alterations in
synaptic function69 suggested to be beneficial in schiz-
ophrenia and HD.67 In the R6/2 mouse, PDE10A inhi-
bition with TP-10 ameliorated motor deficits, reduced
striatal atrophy and increased brain-derived neurotro-
phic factor (BDNF) levels.70 Detailed study of
PDE10A and its pharmacological inhibition is under-
way to validate it as a target in HD. One concern is
that early death of striatal neurons might deplete
PDE10A levels to the extent that the target is lost;
however, PET imaging with the PDE10A radioligand
[18F]-MNI-695 suggests that enzyme levels are suffi-
cient even in manifest HD to expect a meaningful
response.71 Clinical trials of PDE10A inhibition in HD
patients are already underway, with motor and func-
tional MRI endpoints.72 Other phosphodiesterases
implicated in HD pathogenesis are also under study.
PDE4 inhibition with rolipram, meanwhile, improved
survival and ameliorated neuropathology and motor
phenotypes in the R6/2 mouse.73
Mitogen-Activated Protein Kinase
Cell Signaling
Mitogen-activated protein kinase (MAPK) signaling
is involved in the regulation of many cellular functions
in response to a variety of stimuli. Abnormal MAPK
signaling is a feature of HD; in particular, the MAPKs
JNK (c-Jun terminal kinases), ERK (extracellular
signal-regulated kinases), and p38, and the upstream
kinase mixed lineage kinase 2 (MLK2), are overactive
in HD.74-76 One effect of this may be impaired axonal
transport, caused by JNK3-induced phosphorylation
of kinesin-1.77 Additionally, p38 overactivity may con-
tribute to NMDA-receptor–mediated excitotoxicity.78
Extracellular signal-regulated kinase overactivation is
complex and may overall be protective in the presence
of mHTT.76 Treatment of R6/2 mice with sodium
butyrate was neuroprotective and extended survival; it
also induced upregulation of MKP-1, a negative regu-
lator of MAPK signaling.79 However, sodium butyrate
likely acts via multiple mechanisms. Recently, specific
overexpression of MKP-1 was shown to exert neuro-
protective effects against mHTT through inhibition of
JNK and p38.80 Pharmacological MLK2 inhibition
reduced toxicity in several model systems and
increased motor performance and BDNF levels in the
R6/2 mouse.81 Small-molecule approaches to activate
MKP-1 and ERK, or to inhibit MLK2, JNK, and p38,
may be of value, but these pathways, their role in HD,
and the optimal targets and means of modulating
them are incompletely understood.
Neurotrophic Factors
Depletion of BDNF is a well-established feature of
the HD brain. Produced by cortical neurons, BDNF
promotes neuronal growth, survival, and plasticity. It
is particularly important for the survival of striatal
neurons that are affected prominently in HD and may
protect against excitotoxicity.82 Several mechanisms
have been implicated in the depletion of BDNF in
HD, including transcriptional dysregulation83 and
reduced axonal transport.84 Restoration of BDNF lev-
els, or those of related neurotrophins such as glial
cell–derived neurotrophic factor (GDNF), is of inter-
est, but the challenges of delivering a protein-based
therapeutic to the CNS are considerable. Delivery of
BDNF and GDNF using viral85 or stem-cell86 vehicles
has shown some potential. Clinical trials in Parkin-
son’s disease (PD) patients have demonstrated that
intraparenchymal AAV-mediated delivery of the
GDNF analog neurturin to the putamen is safe and
well-tolerated but have yet to meet a primary efficacy
endpoint.87 Postmortem analysis has confirmed suc-
cessful induction and sustained expression of neu-
rturin. A recently completed phase 2b trial has been
reported as again meeting safety but not efficacy end-
points.88 One reason for efficacy failure of this
approach may be the difficulty of identifying PD
patients sufficiently early to intervene successfully. The
monogenic, penetrant nature of HD perhaps makes it
more amenable to this approach to neurotrophin
delivery, because treatment could be initiated early in
the disease or even before symptom onset.
BDNF acts principally through binding to TrkB
receptors, and one approach to overcome the limita-
tions of a protein-based therapeutic has been to
develop small-molecule TrkB agonists. Several experi-
mental compounds have now been tested in HD rodent
models. Jiang and colleagues orally administered two
presumed TrkB agonists (7,8-DHF and 40-DMA-7,8-
DHF) to N171-82Q mice and showed increased stria-
tal TrkB phosphorylation, significantly improved
motor function, increased lifespan, and reduced brain
atrophy in treated animals.89 Simmons and col-
leagues90 demonstrated similar benefits from another
TrkB agonist, LM22A-4, in the R6/2 and BACHD
models, and additionally showed reduced intranuclear
aggregation of mHTT in striatum and cortex.
However, Todd and colleagues91 compared 7,8-
DHF, LM22A-4, and other reported small-molecule
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TrkB agonists. In contrast to previous reports, all
tested compounds displayed a lack of TrkB agonism,
no activation of relevant pathways, and no neuropro-
tection against mHTT in corticostriatal co-culture.
However, two monoclonal antibodies were shown to
agonize TrkB in a manner akin to BDNF and pro-
tected striatal neurons from mHTT-induced toxicity.
Though challenging, the use of monoclonal antibodies
as BDNF mimics warrants further study.91
An innovative approach to restoring neurotrophic
support in HD is to target the transcriptional dysregu-
lation that partly underlies the BDNF deficiency in
HD. Abnormal repression of BDNF expression by the
transcription factor REST/NRSF has been demon-
strated in HD. Conforti and colleagues92 screened for
compounds capable of inhibiting the formation of the
REST-mSIN3 complex that is required for transcrip-
tional repression. They identified a compound, C91,
that increased BDNF mRNA levels in Htt-knockdown
and mHTT-expressing zebrafish models.92 This novel
approach is in its infancy but offers another avenue
for rescuing the BDNF deficit in HD.
Finally, the FDA-approved compound cysteamine is
thought to increase brain levels of BDNF by stimulat-
ing its release through an interaction with the heat-
shock protein HSJ1b.93 A recent trial of cysteamine in
HD patients has recently completed, but although a
suggestion of motor improvement occurred in a sub-
group analysis, the primary efficacy endpoint was not
met; the full results of the trial, and its open-label
extension, are awaited.94
Modulation of Glial Activity
Although the clinical features of HD are undoubt-
edly driven by cell-autonomous effects of mHTT caus-
ing neuronal dysfunction and death, the role of non-
neuronal cells in the pathobiology of HD is increas-
ingly a focus for study and as a source of tractable
therapeutic targets. Huntingtin is ubiquitously
expressed, and glial cells may display cell-autonomous
dysfunctions of their own,95 which may exacerbate an
already precarious situation for neurons.
Excitotoxicity is a long-hypothesized contributor to
neuronal dysfunction and death in HD. The earliest HD
models were generated by intrastriatal injection of the
excitotoxic NMDA agonist quinolinic acid (QA) in
rodents.96 Quinolinic acid is an endogenous metabolite
produced by the degradation of tryptophan by the kyn-
urenine pathway. The enzyme kynurenine monooxygen-
ase (KMO) is a key branchpoint in this pathway, and
its activity determines the balance of QA and the neuro-
protectant metabolites kynurenic acid (KA) and kynu-
renine. In the CNS, the kynurenine pathway is confined
to microglial cells.97 QA levels are increased and KA
levels decreased in post-mortem HD patient brain.98,99
A yeast genomic screen highlighted KMO as a leading
therapeutic target,100 and subsequent work in drosoph-
ila has confirmed this.101 Zwilling and colleagues102
treated R6/2 HD model mice with a KMO inhibitor
compound, JM6, and found increased brain levels of
KA and decreased glutamate. Treated animals displayed
improved survival, reduced loss of the synaptic marker
synaptophysin, and a decrease in abnormal microglial
activation. Neither JM6 nor its metabolites cross the
blood–brain barrier, suggesting that its beneficial effects
are mediated by peripheral KMO inhibition, producing
beneficial effects for the CNS via the transit of an inter-
mediate compound, possibly kynurenine.102 Subsequent
work by Beconi and colleagues120 has questioned the
status of JM6 as a KMO inhibitor, suggesting that the
observed effects were likely attributable to contamina-
tion by the known KMO inhibitor Ro-61-8048; how-
ever, the status of KMO inhibition, peripherally or
centrally, as a therapeutic target remains strong. Indeed
a novel peripherally acting KMO inhibitor, CHDI-
340246, has been reported to increase levels of kynuren-
ine and KA in HD rodent models and the cerebrospinal
fluid of nonhuman primates.103
Hyperactivity of the innate immune system, both cen-
trally and peripherally, as a result of the cell-
autonomous effects of mHTT in monocytes and micro-
glia, and mediated by the nuclear factor kappa B
(NFjB) pathway, is now an established pathogenic path-
way in HD.95,104 Whether immunomodulation by any of
the wide array of agents available is capable of prevent-
ing or reversing this detectable phenotype, and whether
this will prove beneficial in patients, remains to be seen.
Although its precise mechanism of action is unknown,
the immunomodulator laquinimod reduces (NFjB) acti-
vation in astrocytes105 and may restore BDNF levels.106
Laquinimod also may act in part through the MAPK sig-
naling pathway, reducing the phosphorylation of p38
and JNK,107 linking this compound to the cell signaling
pathways discussed previously. Having demonstrated
potential in multiple sclerosis,108 laquinimod’s effects on
tractable dysfunctions in HD are under investigation,
and clinical trials in HD are planned.
CB2 cannabinoid receptors are expressed in micro-
glia and peripheral immune cells; their activation is
anti-inflammatory, and their levels are increased in
postmortem HD brain. Genetic deletion of CB2 recep-
tors was found to accelerate the phenotype in bacterial
artificial chromosome HD (BACHD) mice, whereas
treatment with the CB2 agonist GW405833 amelio-
rated it and prolonged survival. This effect was
reversed by co-administration of a peripherally acting
CB2 antagonist, suggesting again that peripheral
immunomodulation may be capable of altering the
CNS phenotype of HD.109
The microglial and neuronal P2X7 receptor is an
adenosine triphosphate–gated ion channel that has
been found to be overexpressed in synaptic terminals
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in HD.110 Extracellular adenosine triphosphate, acting
on this receptor, stimulates synaptic dysregulation and
neuronal death through apoptotic and nonapoptotic
mechanisms111; in HD model mice, a P2X7 antagonist
reduced apoptotic neuronal death, weight loss, and
motor deficits.110 P2X7 in both neurons and microglia
is under investigation as a potential therapeutic target.
Extracellular glutamate, which may contribute to
excitotoxic neuronal death, is predominantly (90%)
removed by excitatory amino acid transporter 2
(EAAT2), predominantly expressed in astrocytes.112
EAAT2 and its ortholog GLT1 show reduced expression
in the R6/2 mouse and human HD brain113,114 although
whether receptor deficiency is the cause of impaired glu-
tamate in HD striatum is less clear.115 EAAT2 expres-
sion may be amenable to pharmacological modulation
through activation of its promoter by the antibiotic cef-
triaxone.116 In one study, ceftriaxone treatment
increased overall receptor expression and ameliorated
motor deficits in R6/2 mice.115 Whether EAAT2 in rele-
vant cell populations is amenable to sustained pharma-
cological upregulation in HD, and whether this will be
beneficial in patients, remains to be seen.
Metabolism
Numerous alterations of cellular energetic mecha-
nisms have been described in HD, albeit with inconsis-
tent findings, especially comparing animal and human
studies117; however, an association between energetic
TABLE 1. Summary of current priority preclinical therapeutic targets in Huntington’s diseasea
Mechanism/Target Compound Tested in Entity Ref
HTT lowering by RNAi Allele-nonspecific siRNA, intrastriatal convection-enhanced
delivery
NHP Alnylam Inc. / Medtronic, Inc. 21
Allele-nonspecific siRNA, AAV delivery, intrastriatal injection NHP Medtronic Inc. 20
Allele-nonspecific miRNA, AAV delivery, intrastriatal injection NHP U. Iowa 19
Allele-nonspecific siRNA, cholesterol-conjugated,
intrastriatal injection
Mouse MGH / UMass / Alnylam Inc. 26
Allele-specific single-stranded siRNA, intraventricular
infusion
Mouse UTSW / UCSD / Isis 28
HTT lowering by ASO Allele-nonspecific ASO, intrathecal injection NHP Isis 22
Allele-specific ASO, intrastriatal injection Mouse UBC / Isis 7
Allele-specific CAG-targeted ASO Cells U. Leiden / Prosensa 23
HTT lowering by ZFP Allele-specific ZFP transcriptional repressor,
AAV delivery, intrastriatal injection
Mouse EMBL/CRG SBRU 3
Sangamo 3
Posttranslational modification Kinase inhibition Cells McMaster U. 38
Ganglioside GM1, intraventricular infusion Mouse McMaster U. 41
Chaperone enhancement Genetic overexpression of HSJ1a Mouse KCL 44
Recombinant ApiCCT1 Cells UC Irvine / Stanford- 47
Autophagy enhancers Trehalose, calpastatin, nicardipine, minoxidil Mouse Various 50
Acetylation promoter (selisistat) Human Siena Biotech 52, 54
Aggregation prevention HDAC4 genetic knockdown Mouse KCL 57
Small molecule HDAC4 inhibition Mouse CHDI 61
Phosphodiesterase 10A
inhibition
PF-2545920 Human Pfizer 72
OMS643762 Human Omeros 120
MAPK cell signaling JNK/p38 inhibition via MKP-1 overexpression Mouse EPFL 80
MLK2 inhibition by CEP-1347 Mouse UC Irvine 81
Neurotrophic support TrkB agonists (7,8-DHF / 40-DMA-7,8-DHF) Mouse Johns Hopkins 89
TrkB agonist (LM22A-4) Mouse Stanford 90
TrkB agonist (monoclonal antibody) Cells CHDI 91
BDNF transcriptional activation Zebrafish U. Milano 92
Cysteamine Human Raptor 94
KMO inhibition JM6 / Ro-61-8048 Mouse UCSF 102
CHDI-340246 NHP CHDI 103
Immunomodulation Laquinimod Human (MS) Teva 108
CB2 agonist (GW405833) Mouse UCSF 109
P2X7 antagonism Brilliant blue G Mouse CSIC/UAM 110
Astrocytic glutamate uptake EAAT2 promoter activation (ceftriaxone) Mouse U. Indiana 115
a‘Tested in’ refers to most advanced model or organism in which successful target modulation has been demonstrated.
HTT, huntingtin protein; RNAi, RNA interference; siRNA, short interfering RNA; NHP, non-human primate; AAV, adeno-associated virus; miRNA, microRNA;
MGH, Massachusetts General Hospital; ASO, antisense oligonucleotide; UBC, University of British Colombia; ZFP, zinc finger proteins; EMBL/CRG SBRU,
European Molecular Biology Laboratory Systems Biology Research Unit; HSJ1a, Homo sapiens J domain protein 1a; ApiCCT1, apical domain of chaperonin
containing T-complex protein-1/T-complex protein-1 ring subunit CCT1; KCL, King’s College London; MAPK, mitogen-activated protein kinase; JNK, c-Jun ter-
minal kinases; MKP-1, MAP kinase phosphatase 1; EPFL, Ecole polytechnique federale de Lausanne; TrkB, tropomyosin-related kinase B; BDNF, brain-derived
neurotrophic factor; UCSF, University of California San Francisco; KMO, kynurenine monooxygenase; MS, multiple sclerosis; CB2, cannabinoid Receptor 2;
P2X7, purine receptor 2X7; CSIC, Consejo Superior de Investigaciones Cientıficas; UAM, Universidad Autonoma de Madrid; EAAT2, excitatory amino acid
transporter 2.
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deficits and the length of the CAG triplet repeat
presents a compelling case for a direct causation by
the mutant gene.118 Human trials of several antioxi-
dant molecules have not yielded any clear therapeutic
success, however, and improvement of our under-
standing of HD-specific metabolic derangements is
needed to develop more targeted therapeutics.117
Modulation of the metabolic transcriptional coactiva-
tor Peroxisome proliferator-activated receptor-gamma
coactivator (PGC1a), perhaps through agonism of the
nuclear receptor peroxisome proliferator-activated
receptor gamma by rosiglitazone, has been reported as
ameliorating motor deficits and increasing cortical
BDNF in an HD mouse model, although apparently
without effect on striatal pathology.119 A much
improved understanding of the complex metabolic
effects of mHTT is needed.
Conclusion
As our understanding of the consequences of the HD
mutation increases, so the range of tractable targets for
therapeutic development broadens. While there are
many potential targets, few are well-validated, and
many single studies of purported success have yet to be
replicated. Another problem is the shortcomings of our
model systems and the failure, so far, of any agent that
has been beneficial in an HD mouse model to prove so
in human patients. Insights from studying patients are
likely to be key to bridging this so-called “valley of
death”: increasingly we are inclined and able to dem-
onstrate relevant derangements in patients or patient-
derived tissue before embarking on expensive and
potentially hazardous clinical trials. Our understanding
of therapeutic targets36 and our ability to prosecute
them is better than ever, thanks in part to the increas-
ingly prominent, concerted involvement of medicinal
chemists in the field,61 and we anticipate an exciting
era in the near future in which multiple agents,
designed specifically to target the known pathobiology
of HD, will enter clinical trials with a reasonable
expectation of success.
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